(71 days)
None
Not Found
No
The summary describes a qualitative detection method for occult blood in feces, which is a chemical or immunoassay-based test, not a technology typically associated with AI/ML. There are no mentions of AI, ML, image processing, or data analysis techniques that would suggest the use of these technologies.
No.
The device is described as a qualitative detection method for occult blood in feces, used as a screening test. It does not provide treatment or therapy.
Yes
The device is described as a "method for the qualitative detection of occult blood in feces, which may be indicative of gastrointestinal diseases associated with bleeding such as colorectal carcinoma, Crohn's disease, ulcerative colitis, and colon polyp." This indicates its use to identify potential medical conditions, which falls under the definition of a diagnostic device.
No
The summary describes a method for detecting occult blood in feces, which strongly implies a physical test kit or device is involved, not just software. The description of "highly sensitive (0.05 µg hHb/ml)" refers to the performance of a physical test, not software.
Based on the provided information, yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states that ColonCARE is a method for the "qualitative detection of occult blood in feces." This involves testing a sample taken from the human body (feces) in vitro (outside the body) to gain information about a person's health status (presence of occult blood, which may indicate gastrointestinal diseases).
- Sample Type: The test analyzes "feces," which is a biological specimen.
- Purpose: The purpose is to detect a substance (occult blood) that is indicative of a disease or condition (gastrointestinal diseases, colorectal carcinoma, etc.).
These are all key characteristics of an In Vitro Diagnostic device as defined by regulatory bodies like the FDA.
N/A
Intended Use / Indications for Use
ColonCARE is a rapid, convenient, hygienic and highly sensitive (0.05 µg hHb/ml) method for the qualitative detection of occult blood in feces, which may be indicative of gastrointestinal diseases associated with bleeding such as colorectal carcinoma, Crohn's disease, ulcerative colitis, and colon polyp:
The test is recommended for use in the home or in medical facilities as a screening test for colorectal cance or gastrointestinal bleeding from any source.
Product codes
KHE
Device Description
Not Found
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
the home or in medical facilities
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Not Found
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
highly sensitive (0.05 µg hHb/ml)
Predicate Device(s)
Not Found
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 864.6550 Occult blood test.
(a)
Identification. An occult blood test is a device used to detect occult blood in urine or feces. (Occult blood is blood present in such small quantities that it can be detected only by chemical tests of suspected material, or by microscopic or spectroscopic examination.)(b)
Classification. Class II (special controls). A control intended for use with an occult blood test is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 864.9.
0
Image /page/0/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a circular border with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the top half of the circle. Inside the circle is a stylized image of three human profiles facing to the right, stacked on top of each other. The profiles are abstract and created with thick, curved lines.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
APR 0 2 2003
Mr. Paul Swift Sales Manager Care Products, Inc. 231 Bank Street Waterbury. Connecticut 06702
Re: K030216
Trade/Device Name: ColonCARE Regulation Number: 21 CFR § 864.6550 Regulation Name: Occult Blood Test Regulatory Class: II Product Code: KHE Dated: March 10, 2003 Received: March 26, 2003
Dear Mr. Swift :
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it ' may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
1
Page 2 -
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
Steven Sutman
Steven I. Gutman, M.D., M.B.A. Director Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
2
| 510(k) Number (if known): | K030216 |
|---|---|
| Device Name: | ColonCARE |
Indications For Use:
ColonCARE is a rapid, convenient, hygienic and highly sensitive (0.05 µg hHb/ml) method for the qualitative detection of occult blood in feces, which may be indicative of gastrointestinal diseases associated with bleeding such as colorectal carcinoma, Crohn's disease, ulcerative colitis, and colon polyp:
The test is recommended for use in the home or in medical facilities as a screening test for colorectal cance or gastrointestinal bleeding from any source.
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use
(Per 21 CFR 801.109)
OR
Over-The-Counter Use
(Optional Format 1-2-96)
Josephine Bautista
(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K030216
SIka9